Cannabis Rescheduling

Congressman Blumenauer Calls Marijuana Schedule III Status 'A Revolutionary Step' But 'Not Quite What We Wanted,' Here's Why
DEA And Cannabis Rescheduling: A Rollercoaster Ride You Don't Want To Miss, But Keep Your Seatbelts On
GOP Senator Bashes Dems' Push For Marijuana Legalization As Pro-Criminal & Anti-American: 'It's Obscene'
DEA And Cannabis Rescheduling: A Rollercoaster Ride You Don't Want To Miss, But Keep Your Seatbelts On
GOP Senator Bashes Dems' Push For Marijuana Legalization As Pro-Criminal & Anti-American: 'It's Obscene'
Former FDA Agent Says Big Pharma Not Likely To Get Involved In Cannabis Industry After Rescheduling
Canadian Giant SNDL Speeds Up Acquisition Of Majority Positions In Two US Cannabis Companies As Marijuana Rescheduling Looms

Cannabis Rescheduling Recent News

Billions On The Move: Tracking Market Cap Changes In Top Cannabis Firms After DEA Rescheduling Announcement
Tuesday's announcement that the DEA is moving towards rescheduling cannabis from Schedule I to Schedule III, has already injected billions into the publicly traded market for cannabis companies.
Lawmakers Warren, Schumer, Fetterman, Lankford And Others On DEA's 'Common Sense' Or 'Irresponsible' Cannabis Rescheduling
Rep Blumenauer On Marijuana Reclassification: 'Legalization Is Inevitable, Biden-Harris Admin Is Listening' To The People
In a landmark decision that could reshape the landscape of American drug policy, the U.S.
DEA's Move To Reclassify Cannabis Seen As 'Significant,' But Fails To Resolve State-Federal Conflict
DEA calls for reclassification of botanical cannabis from Schedule I to III under federal law. NORML praises decision but cautions on state/federal divide.
Cannabis Stocks And ETFs Surge As DEA Moves To Reschedule Marijuana
The cannabis sector saw a notable upswing on Tuesday on news of the Drug Enforcement Administration's (DEA) historic decision to align its stance with a recommendation from the Department of Health and Human Services and move
The Medical Cannabis Explosion Just Got Real
The global cannabis trifecta has hit! The United States has finally rescheduled cannabis, moving it to Schedule III; the Department of Health and Human Services (HHS) and Food and Drug Administration (FDA) have released a report deeming cannabis a safe medicine; and Germany has removed the narcotics derivation from cannabis, making it easy to prescribe. 
DEA Public Comment Period And A Cannabis-Related Crypto Bill? You Heard It First At Benzinga Conference
In Beacon Securities's latest report issued after the Benzinga Cannabis Capital Conference in Florida, analysts delved into significant developments and key conversations that are shaping the future of the cannabis industry.
Canopy Is 'Cautiously Optimistic' On Cannabis Rescheduling Following Major Step Toward Entry Into US THC Market
Canopy Growth's shareholders gave a green light to the creation of a new class of exchangeable shares of the company during their special meeting held on Friday, April 12, as recommended earlier by Institutional Shareholder Services (ISS).At the meeting, shareholders passed a special resolution authorizing an amendment to the company's articles of incorporation, as amended, to create and authorize the issuance of an unlimited number of a new class of non-voting and non-participating exchangeable shares in the capital of Canopy Growth.A total of 32,250,578 common shares of Canopy, representing 35.40% of the issued and outstanding shares, were voted in connection with the meeting by the company's shareholders and proxyholders.he move enables the acceleration of Canopy Growth's entry into the U.S. THC market, which is forecasted to hit roughly $50 billion in 2026, the company said on Monday in a press release.
Biden Champions Cannabis Reform And Pardon As Election Pressure Mounts, Marijuana Takes Center Stage
Governor Polis Calls For Federal Cannabis Rescheduling, Launches New State Business Program
Governor Jared Polis (D and the Cannabis Business Office of the Colorado Office of Economic Development & International Trade recently unveiled a new initiative to improve opportunities for local social equity cannabis businesses.
Future-Proofing The Cannabis Industry: CEO Forecasts M&A Trends And Moves On Emerging Markets
Panther Group CEO Jordan Tritt unveils insights on cannabis M&A, investment trends, and policy impacts. Discover the future of the industry.
DEA Comes Out Of The Shadows To Ensure Cannabis Rescheduling Process Is Not Being Done Under 'Shroud Of Secrecy'
The DEA's silence beyond acknowledging the receipt of the U.S. Department of Health and Human Services (HHS) suggestion to reclassify marijuana has been a source of frustration for advocates and legislators, including co-chairs of the Congressional Cannabis Caucus Rep. Barbara Lee (D-CA) and Rep. Earl Blumenauer, (D-OR) who have complained about the DEA's lack of transparency.
VP Harris, DEA, FDA Eye Cannabis: Key Changes Ahead, Here's What One Expert Predicts
Vice President Harris's urgent call to the DEA to expedite the rescheduling of cannabis marks a crucial turning point in national drug policy, as analyzed in a comprehensive equity research report by Zuanic & Associates.
VP Kamala Harris Urges DEA To Reschedule Cannabis 'As Quickly As Possible,' Calls Prohibition 'Absurd' & 'Unfair'
In a significant move to address long-standing issues within the U.S.
Cannabis Stocks Jump On News That DEA May Soon Undertake Marijuana Reform
Doug Kass, world-renowned hedge fund manager, posted on X, formerly Twitter, Friday that the "DEA will approve a rescheduling of cannabis to Schedule III." 
DEA Vs. White House: Agency Pushes Back On Medical Benefits Of Cannabis, Weed Stocks Wobble
In addition to reportedly doubting the scientific evidence presented by HHS, the DEA also expressed concern about the increasing potency of THC, the psychoactive compound in cannabis. Marijuana advocates and stakeholders question the motivations behind these anonymous claims, as the DEA itself has not publicly opposed the recommendation. The agency is conducting its own review, with Administrator Anne Milgram promising to consider all available research.
Cannabis Industry Veteran On Market Trends, DEA Rescheduling, THC Types, Psychedelics And More
In a recent podcast, David Traylor shares insights on the evolving cannabis and psychedelics industries, advocating for scientific research and financial fortitude amidst regulatory challenges.
[Video] Cannabis Industry's 2024 Outlook: Expert Analysis From Highway 33 Capital Advisory
Cannabis Operators Are Not Risk-Takers Living On The Edge, Most Are Compliant, Says Marijuana Lawyer
Biden Admin Official Denies Cannabis Shift Rumors, Gen-Zers Say They Can Drive Stoned, FLA Caps Weed Strength & More Updates
DEA Poised To Reschedule Cannabis This Week? Something's Brewing In The White House, Says This Insider
The Drug Enforcement Administration (DEA) is apparently on the verge of rescheduling cannabis, potentially within days or weeks. The move would mark the most significant federal action toward marijuana legalization since its prohibition nearly a century ago.
Biden's Weed Promise, The Federal Govt. & 2024 Elections: Analyzing Stock Values, Taxes & Timing
Amidst President Joe Biden’s campaign promises, rescheduling marijuana from Schedule I to Schedule III is seen as the most impactful on the stock market, possibly positively fueling stock rallies.
Senator Gillibrand Urges Biden Administration To Deschedule Marijuana: 'It's A Medical Issue And It's A Public Safety Issue'
Gillibrand urges Biden admin to deschedule cannabis for social justice, economic, medical and public safety reasons. Rescheduling to Schedule III won't do enough.